Literature DB >> 10840396

Effect of long-term vigabatrin administration on the immature rat brain.

M Qiao1, K L Malisza, M R Del Bigio, P Kozlowski, S S Seshia, U I Tuor.   

Abstract

PURPOSE: To determine whether the neuropathologic changes produced by vigabatrin (VGB; gamma-vinyl GABA) administration in the developing rat brain are reversible.
METHODS: We injected rats daily with VGB (25-40 mg/kg/day, s.c.) from age 12 days for 2 weeks followed by 2 weeks of a drug-free period. Behavioral testing, magnetic resonance (MR) imaging, biochemical assays, and histologic technique were used to assess the adverse effect of VGB in developing brain and its reversibility.
RESULTS: At the end of 2 weeks' VGB administration: (a) there was a hyperactivity and a shortened latency to escape out of cool water; (b) white matter appeared hyperintense in T2 and diffusion-weighted MR images with 4-15% increases in T2; (c) microvacuolation, TUNEL-positive nuclei, and swollen axons were observed in the corpus callosum; (d) myelin staining indicated a reduction in myelination, as did the reduction in activities of myelin and oligodendrocyte-associated enzymes and the decrease in myelin basic protein on Western blots. Two weeks after stopping VGB administration: (a) MR images were normal, and microvacuolation was no longer in the white matter; (b) reduction in myelination reversed partially; (c) the T2 relaxation time remained elevated in the hypothalamus; and (d) the behavioral response remained abnormal.
CONCLUSIONS: Long-term VGB administration to young rats causes brain injury, which recovers partially on its cessation. The observed cell death, disrupted myelination, and alterations in behavior indicate a need for further safety assessment in infants and children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840396     DOI: 10.1111/j.1528-1157.2000.tb00225.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

2.  Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample.

Authors:  Po H Lu; Grace J Lee; Erika P Raven; Kathleen Tingus; Theresa Khoo; Paul M Thompson; George Bartzokis
Journal:  J Clin Exp Neuropsychol       Date:  2011-08-26       Impact factor: 2.475

Review 3.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

4.  Gender-specific effect of Mthfr genotype and neonatal vigabatrin interaction on synaptic proteins in mouse cortex.

Authors:  Elinor Blumkin; Tamar Levav-Rabkin; Osnat Melamed; Dalia Galron; Hava M Golan
Journal:  Neuropsychopharmacology       Date:  2011-04-13       Impact factor: 7.853

5.  Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats.

Authors:  Deepa Singh; Sunder Lal Jethani; Aksh Dubey
Journal:  J Clin Diagn Res       Date:  2013-11-10

6.  Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin.

Authors:  G N Simao; S Zarei Mahmoodabadi; O C Snead; C Go; E Widjaja
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-26       Impact factor: 3.825

Review 7.  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.

Authors:  P L Pearl; K M Gibson; M A Cortez; Y Wu; O Carter Snead; I Knerr; K Forester; J M Pettiford; C Jakobs; W H Theodore
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

8.  Lifespan trajectory of myelin integrity and maximum motor speed.

Authors:  George Bartzokis; Po H Lu; Kathleen Tingus; Mario F Mendez; Aurore Richard; Douglas G Peters; Bolanle Oluwadara; Katherine A Barrall; J Paul Finn; Pablo Villablanca; Paul M Thompson; Jim Mintz
Journal:  Neurobiol Aging       Date:  2008-10-15       Impact factor: 4.673

Review 9.  Visual field defects and other ophthalmological disturbances associated with vigabatrin.

Authors:  S J Spence; R Sankar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

10.  Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.

Authors:  Marwa Abd El-Kader; Eman Hamza; Randa El-Gamal; Amira Sobhy Rashed Eladl; Eman Mohamad El Nashar; Mansour A Alghamdi; Omnia S Erfan
Journal:  J Mol Histol       Date:  2021-05-27       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.